ReviewmSphere2025
Opportunities, challenges, and policy implications of the aerobiome paradigm shift.
Review in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Historically, bioaerosol research has focused on identifying and mitigating the harmful effects of airborne pathogens and particles. These bioaerosols-including bacteria, viruses, fungal spores, and non-biological particles, such as particulate matter up to 2.5 µm (PM2.5)-pose substantial risks to human and ecosystem health. They can contribute to diseases and adverse outcomes in humans, animals, plants, and their associated microbial communities. Researchers have concentrated on understanding transmission mechanisms, detecting and quantifying these agents, and developing control strategies. However, a recent paradigm shift in aerobiome thinking highlights the importance of beneficial bioaerosols in maintaining ecosystem and human health. Beneficial bioaerosols, such as salutogenic (health-promoting) microbiota, phytoncides (plant-derived organic compounds), pheromones, and potentially "aeronutrients" contribute to human health modulation and important ecosystem processes. This dual nature of bioaerosols necessitates a holistic approach to promote beneficial components while mitigating harmful ones. Here, we introduce a recently established initiative called the Aerobiome Innovation and Research Hub (AIR Hub), which aims to advance this interdisciplinary research. We call for action to further understand and leverage the beneficial biological components of air for both human and ecosystem health and present the results of an AIR Hub workshop "reverse brainstorming" session to identify novel opportunities and challenges. These include key barriers to advancing aerobiome science, such as poor communication, methodological complexity, and fragmented regulation. Solutions focused on clearer definitions, improved research methods, targeted communication, and stronger policy engagement. Finally, we present the key policy implications of advancing this aerobiome paradigm shift.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.